Nuvilex (NASDAQ:PMCB – Get Free Report)‘s stock had its “sell (d)” rating reissued by investment analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.
Nuvilex Trading Up 1.8%
Shares of PMCB opened at $0.98 on Friday. The firm’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.04. The firm has a market capitalization of $6.64 million, a price-to-earnings ratio of -1.81 and a beta of -0.05. Nuvilex has a 1-year low of $0.80 and a 1-year high of $2.42.
Nuvilex (NASDAQ:PMCB – Get Free Report) last announced its earnings results on Monday, September 15th. The company reported ($0.09) earnings per share for the quarter.
About Nuvilex
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Featured Stories
- Five stocks we like better than Nuvilex
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- What Are Dividend Challengers?
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- Stock Market Upgrades: What Are They?
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
